More General News
View Older Stories View Newer Stories-
Micron stays a buy rating at BofA on memory supply outlook and tech gains
-
BofA tracks shipping data showing Red Sea transit recovery
-
Goldman Sachs forecasts two Bank of Canada rate hikes by January
-
Raymond James survey shows Trutakna matching Voyxact launch pace
-
Banks show continued growth as third quarter results roll in
-
Citi reiterates Buy rating on Instacart amid reported sale talks
-
Instacart jumps 10% on report of potential sale to Uber or DoorDash
-
OpenAI mandates offline training for frontier models to prevent AI escapes
-
Top restaurant stocks to watch, according to Raymond James
-
Investing.com’s stocks of the week
-
Lycia Therapeutics surges in debut following upsized $317.5M IPO
-
OptionMetrics flags hidden gems in commodities as wheat, soybeans outshine copper
-
Goldman Sachs sees US stocks dip on tech earnings and macro shifts
-
BP, Louisiana agree to Deepwater Horizon settlement payout, resolve coastal cases
-
Iran has detailed plans to hit Gulf undersea cables if war resumes, officials say
-
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
-
Micron, Sandisk gain as SK Hynix scraps Solidigm IPO, LYNX says
-
Wells Fargo Names Top Pick Ahead of Q3 Earnings
-
Truist names top clean energy stocks to watch ahead of Q3 earnings season
-
AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
-
AI-powered cyber threats light a fire under cybersecurity stocks
-
Shein agrees to $100M FTC settlement as regulatory pressure mounts - Reuters
-
Meta’s new non-voting shares aim to protect Zuckerberg’s control: Oppenheimer
-
Credo slides 7.5% as competition, slower 1.6T rollout weigh
-
Infosys falls despite revenue beat as guidance disappoints
-
BofA names Meta a top AI pick, raises price target on stronger ad growth
-
Evercore Highlights 2 Cybersecurity Stocks as Demand Strengthens Into Year-End
-
Zymeworks stock surges on $813M Roche licensing deal
-
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
-
Robert Half stock rises as analysts lift targets after Q3 results
-
Buy pullback in this chip stock, Mizuho says
-
Infosys’ U.S. shares tumble after revenue outlook cut
-
AmEx CEO says company to cut 5% of total workforce
-
Cboe Global Markets stock gains on $550M buyback boost
-
'Truly something cool': Apple fans react as iPhone Duo hits stores
-
Meta's capital-raising plans expose a major weakness in the AI boom
-
BofA Names Preferred Picks Among European Chipmakers Ahead of Earnings
-
LKQ stock tumbles 10% on weak Q3 results, CEO departure
-
RBC upgrades Sartorius on improving growth outlook, AI-driven research demand
-
Premarket movers: Crown Castle jumps 7.5% on SpaceX talks; Autoliv slides
-
Tango Therapeutics stock falls despite positive cancer trial data
-
Norwegian Cruise Line cut to Underweight by JPMorgan ahead of earnings
-
AI-fueled tech selloff in focus; Western Digital reports - what’s moving markets
-
BofA flags further downside risk for stocks, yields and dollar
-
Flagstar Bank stock falls 5% on third quarter earnings, revenue miss
-
American Express raises annual guidance amid strong billings, customer acquisition
-
BofA sees growing investor reluctance to fund AI infrastructure
-
UBS sees dip buyers stepping in to support gold at this level
-
Autoliv shares fall 5% on third quarter earnings miss
-
Deutsche Bank upgrades Roche on bullish physician feedback for cancer drug
